Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 143 | 2024 | 2895 | 12.900 |
Why?
|
Carcinoma, Squamous Cell | 87 | 2024 | 4026 | 5.640 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 56 | 2024 | 11742 | 3.000 |
Why?
|
Nasopharyngeal Neoplasms | 6 | 2024 | 290 | 2.920 |
Why?
|
Thyroid Neoplasms | 19 | 2023 | 2332 | 2.800 |
Why?
|
Oropharyngeal Neoplasms | 26 | 2023 | 491 | 2.710 |
Why?
|
Neoplasm Recurrence, Local | 54 | 2024 | 9280 | 2.660 |
Why?
|
Papillomavirus Infections | 28 | 2023 | 1613 | 2.360 |
Why?
|
Cisplatin | 22 | 2024 | 1652 | 2.030 |
Why?
|
Mouth Neoplasms | 12 | 2024 | 596 | 1.720 |
Why?
|
Papillomaviridae | 16 | 2024 | 1119 | 1.590 |
Why?
|
Carcinoma, Adenoid Cystic | 8 | 2021 | 262 | 1.520 |
Why?
|
Salivary Gland Neoplasms | 8 | 2020 | 304 | 1.400 |
Why?
|
Antineoplastic Agents | 32 | 2024 | 13642 | 1.380 |
Why?
|
Laryngeal Neoplasms | 8 | 2014 | 514 | 1.340 |
Why?
|
Taxoids | 19 | 2017 | 668 | 1.250 |
Why?
|
Deglutition Disorders | 8 | 2016 | 625 | 1.200 |
Why?
|
Neoadjuvant Therapy | 10 | 2023 | 2827 | 1.160 |
Why?
|
Human papillomavirus 16 | 11 | 2017 | 267 | 1.100 |
Why?
|
Quinazolines | 11 | 2020 | 1371 | 1.090 |
Why?
|
Carcinoma | 8 | 2024 | 2330 | 1.080 |
Why?
|
Carcinoma, Neuroendocrine | 7 | 2022 | 339 | 1.040 |
Why?
|
Carcinoma, Ductal | 2 | 2018 | 97 | 1.010 |
Why?
|
Acupuncture Therapy | 3 | 2016 | 486 | 0.930 |
Why?
|
Radiotherapy, Intensity-Modulated | 14 | 2022 | 801 | 0.930 |
Why?
|
Neoplasm Metastasis | 22 | 2020 | 4915 | 0.910 |
Why?
|
Carboplatin | 18 | 2019 | 794 | 0.840 |
Why?
|
Protein Kinase Inhibitors | 10 | 2023 | 5672 | 0.810 |
Why?
|
Paclitaxel | 16 | 2019 | 1732 | 0.790 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2019 | 646 | 0.780 |
Why?
|
Combined Modality Therapy | 31 | 2020 | 8528 | 0.770 |
Why?
|
Humans | 275 | 2024 | 761572 | 0.740 |
Why?
|
Disease-Free Survival | 25 | 2021 | 6815 | 0.730 |
Why?
|
Neoplasm Staging | 33 | 2024 | 11121 | 0.720 |
Why?
|
Iodine | 1 | 2022 | 288 | 0.690 |
Why?
|
Fluorouracil | 16 | 2019 | 1642 | 0.680 |
Why?
|
Tumor Burden | 7 | 2022 | 1893 | 0.670 |
Why?
|
Stomatitis | 7 | 2020 | 271 | 0.670 |
Why?
|
Neoplasms, Squamous Cell | 3 | 2009 | 95 | 0.640 |
Why?
|
Patient Selection | 7 | 2018 | 4244 | 0.640 |
Why?
|
Aged | 119 | 2024 | 169310 | 0.630 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2019 | 357 | 0.630 |
Why?
|
Tretinoin | 1 | 2021 | 519 | 0.610 |
Why?
|
Azacitidine | 1 | 2019 | 336 | 0.590 |
Why?
|
Middle Aged | 125 | 2024 | 220920 | 0.590 |
Why?
|
Piperidines | 4 | 2020 | 1656 | 0.570 |
Why?
|
Deglutition | 3 | 2013 | 208 | 0.560 |
Why?
|
Iodine Radioisotopes | 6 | 2023 | 1031 | 0.560 |
Why?
|
Male | 150 | 2024 | 360842 | 0.550 |
Why?
|
Carcinoma, Medullary | 4 | 2013 | 115 | 0.540 |
Why?
|
Aged, 80 and over | 54 | 2024 | 58986 | 0.520 |
Why?
|
Medical Oncology | 6 | 2022 | 2321 | 0.520 |
Why?
|
Anilides | 3 | 2018 | 411 | 0.500 |
Why?
|
Female | 143 | 2024 | 392686 | 0.490 |
Why?
|
Chemotherapy, Adjuvant | 12 | 2020 | 3514 | 0.480 |
Why?
|
Xerostomia | 6 | 2010 | 94 | 0.480 |
Why?
|
Laryngectomy | 5 | 2018 | 243 | 0.470 |
Why?
|
Phenylurea Compounds | 2 | 2017 | 529 | 0.460 |
Why?
|
Immunotherapy | 7 | 2024 | 4652 | 0.460 |
Why?
|
Treatment Outcome | 50 | 2023 | 64684 | 0.460 |
Why?
|
Alphapapillomavirus | 2 | 2017 | 218 | 0.450 |
Why?
|
Proteinuria | 1 | 2017 | 607 | 0.450 |
Why?
|
Radiotherapy, Adjuvant | 13 | 2011 | 1784 | 0.450 |
Why?
|
Survival Analysis | 20 | 2020 | 10090 | 0.450 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1062 | 0.440 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2024 | 857 | 0.430 |
Why?
|
Diarrhea | 3 | 2019 | 1318 | 0.410 |
Why?
|
Adult | 92 | 2024 | 221203 | 0.410 |
Why?
|
Neck Dissection | 5 | 2011 | 201 | 0.410 |
Why?
|
Exanthema | 1 | 2017 | 503 | 0.400 |
Why?
|
Methotrexate | 6 | 2019 | 1719 | 0.390 |
Why?
|
Depsipeptides | 1 | 2012 | 95 | 0.390 |
Why?
|
Quinolines | 1 | 2017 | 764 | 0.380 |
Why?
|
DNA, Viral | 8 | 2019 | 2202 | 0.380 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2811 | 0.370 |
Why?
|
Vascular Neoplasms | 1 | 2012 | 166 | 0.370 |
Why?
|
Clinical Trials as Topic | 9 | 2018 | 8002 | 0.370 |
Why?
|
Prognosis | 26 | 2024 | 29629 | 0.360 |
Why?
|
Adenocarcinoma | 7 | 2022 | 6346 | 0.360 |
Why?
|
Fatigue | 2 | 2017 | 1552 | 0.360 |
Why?
|
Lung Neoplasms | 9 | 2024 | 13382 | 0.350 |
Why?
|
Life Expectancy | 1 | 2017 | 1242 | 0.350 |
Why?
|
Spouses | 2 | 2014 | 283 | 0.350 |
Why?
|
Disease Progression | 15 | 2021 | 13510 | 0.340 |
Why?
|
Saliva | 3 | 2019 | 828 | 0.340 |
Why?
|
Thrombophilia | 1 | 2012 | 305 | 0.340 |
Why?
|
Lymph Nodes | 6 | 2023 | 3466 | 0.340 |
Why?
|
Fecal Incontinence | 2 | 2022 | 241 | 0.330 |
Why?
|
Osteoradionecrosis | 2 | 2021 | 51 | 0.330 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3165 | 0.320 |
Why?
|
Platinum | 5 | 2023 | 220 | 0.320 |
Why?
|
Radiotherapy Dosage | 13 | 2022 | 2898 | 0.320 |
Why?
|
Amifostine | 2 | 2009 | 40 | 0.310 |
Why?
|
Angiogenesis Inhibitors | 2 | 2016 | 2047 | 0.310 |
Why?
|
Speech | 1 | 2013 | 554 | 0.310 |
Why?
|
Neutropenia | 3 | 2019 | 885 | 0.300 |
Why?
|
Quinuclidines | 1 | 2007 | 24 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2018 | 5305 | 0.290 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4251 | 0.290 |
Why?
|
Biological Therapy | 1 | 2008 | 141 | 0.290 |
Why?
|
Muscarinic Agonists | 1 | 2007 | 91 | 0.290 |
Why?
|
Neoplasms | 8 | 2023 | 22173 | 0.280 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 774 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 13 | 2019 | 6484 | 0.280 |
Why?
|
Antibodies, Monoclonal | 13 | 2021 | 9177 | 0.280 |
Why?
|
Urinary Bladder, Overactive | 3 | 2019 | 115 | 0.270 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.270 |
Why?
|
Pyridines | 3 | 2018 | 2875 | 0.270 |
Why?
|
Technology, Pharmaceutical | 1 | 2006 | 84 | 0.260 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2019 | 899 | 0.260 |
Why?
|
Double-Blind Method | 8 | 2024 | 12341 | 0.260 |
Why?
|
Thyroidectomy | 5 | 2018 | 908 | 0.260 |
Why?
|
Esophageal Stenosis | 4 | 2013 | 196 | 0.250 |
Why?
|
Retrospective Studies | 40 | 2024 | 80646 | 0.250 |
Why?
|
Mouth | 2 | 2020 | 381 | 0.250 |
Why?
|
Neuromuscular Agents | 2 | 2019 | 147 | 0.240 |
Why?
|
Antibodies, Viral | 5 | 2019 | 3156 | 0.240 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2021 | 698 | 0.240 |
Why?
|
Polymerase Chain Reaction | 7 | 2024 | 6075 | 0.240 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2019 | 101 | 0.230 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2015 | 629 | 0.230 |
Why?
|
Lymphatic Metastasis | 8 | 2015 | 2915 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4580 | 0.230 |
Why?
|
Survival Rate | 13 | 2020 | 12725 | 0.220 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 88 | 0.220 |
Why?
|
Botulinum Toxins, Type A | 2 | 2019 | 237 | 0.220 |
Why?
|
Tropomyosin | 1 | 2023 | 104 | 0.220 |
Why?
|
Thiophenes | 1 | 2007 | 569 | 0.210 |
Why?
|
Retreatment | 4 | 2021 | 598 | 0.210 |
Why?
|
Research Design | 3 | 2015 | 6180 | 0.210 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10212 | 0.210 |
Why?
|
Nocturia | 1 | 2022 | 18 | 0.210 |
Why?
|
Receptor, trkA | 1 | 2023 | 159 | 0.200 |
Why?
|
Standard of Care | 2 | 2023 | 551 | 0.200 |
Why?
|
Quality of Life | 12 | 2024 | 13367 | 0.200 |
Why?
|
Receptor, erbB-2 | 5 | 2020 | 2557 | 0.200 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2023 | 1609 | 0.200 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2007 | 276 | 0.200 |
Why?
|
Precancerous Conditions | 3 | 2024 | 980 | 0.200 |
Why?
|
Salvage Therapy | 3 | 2021 | 1264 | 0.200 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2021 | 2865 | 0.190 |
Why?
|
Tongue Neoplasms | 2 | 2013 | 183 | 0.190 |
Why?
|
Cholinergic Antagonists | 1 | 2022 | 168 | 0.190 |
Why?
|
Larynx | 3 | 2013 | 492 | 0.190 |
Why?
|
Rectal Diseases | 1 | 2022 | 143 | 0.190 |
Why?
|
Skin Neoplasms | 6 | 2021 | 5821 | 0.190 |
Why?
|
Herpesvirus 4, Human | 2 | 2024 | 1078 | 0.180 |
Why?
|
Perineum | 1 | 2022 | 208 | 0.180 |
Why?
|
Oropharynx | 2 | 2013 | 138 | 0.180 |
Why?
|
Urodynamics | 1 | 2022 | 346 | 0.180 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1745 | 0.180 |
Why?
|
Cyclin A | 1 | 2000 | 60 | 0.180 |
Why?
|
Sulfonamides | 4 | 2013 | 1978 | 0.180 |
Why?
|
Gene Fusion | 1 | 2023 | 356 | 0.180 |
Why?
|
Coitus | 1 | 2021 | 132 | 0.180 |
Why?
|
Rhabdomyoma | 1 | 2020 | 56 | 0.180 |
Why?
|
Dilatation | 2 | 2013 | 306 | 0.170 |
Why?
|
Hypopharyngeal Neoplasms | 3 | 2011 | 51 | 0.170 |
Why?
|
Interdisciplinary Communication | 1 | 2006 | 931 | 0.170 |
Why?
|
Remission Induction | 5 | 2009 | 2397 | 0.170 |
Why?
|
Urethra | 1 | 2022 | 405 | 0.170 |
Why?
|
Radiation Injuries | 3 | 2019 | 1189 | 0.170 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 4111 | 0.170 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2018 | 269 | 0.170 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2000 | 189 | 0.160 |
Why?
|
Follow-Up Studies | 18 | 2020 | 39107 | 0.160 |
Why?
|
Erythropoietin | 1 | 2004 | 719 | 0.160 |
Why?
|
Iatrogenic Disease | 1 | 2022 | 539 | 0.160 |
Why?
|
Mouthwashes | 2 | 2016 | 57 | 0.160 |
Why?
|
Salivary Ducts | 1 | 2018 | 25 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2018 | 2057 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 191 | 0.160 |
Why?
|
Immunohistochemistry | 9 | 2016 | 11076 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2015 | 326 | 0.150 |
Why?
|
Prospective Studies | 18 | 2022 | 54426 | 0.150 |
Why?
|
Cough | 1 | 2022 | 594 | 0.150 |
Why?
|
Drug Delivery Systems | 2 | 2008 | 2226 | 0.150 |
Why?
|
Delphi Technique | 1 | 2022 | 846 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 372 | 0.150 |
Why?
|
Mutation | 10 | 2024 | 30054 | 0.150 |
Why?
|
Algorithms | 3 | 2023 | 14032 | 0.150 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1092 | 0.150 |
Why?
|
Melanoma | 4 | 2024 | 5709 | 0.150 |
Why?
|
Pilot Projects | 8 | 2019 | 8633 | 0.150 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 322 | 0.150 |
Why?
|
Quinolones | 1 | 2021 | 378 | 0.150 |
Why?
|
Anemia | 2 | 2004 | 1509 | 0.140 |
Why?
|
Muscarinic Antagonists | 1 | 2018 | 135 | 0.140 |
Why?
|
Orgasm | 1 | 2017 | 61 | 0.140 |
Why?
|
Serologic Tests | 1 | 2019 | 381 | 0.140 |
Why?
|
Papillomavirus E7 Proteins | 3 | 2012 | 109 | 0.140 |
Why?
|
Clinical Protocols | 2 | 2014 | 1440 | 0.140 |
Why?
|
Antigens, Viral, Tumor | 1 | 1997 | 153 | 0.140 |
Why?
|
Urology | 1 | 2022 | 400 | 0.140 |
Why?
|
Simian virus 40 | 1 | 1997 | 291 | 0.140 |
Why?
|
Diaphragm | 1 | 1999 | 351 | 0.140 |
Why?
|
Homocysteine | 3 | 2012 | 638 | 0.140 |
Why?
|
Smoking Cessation | 3 | 2015 | 2057 | 0.140 |
Why?
|
Young Adult | 18 | 2021 | 59255 | 0.140 |
Why?
|
Platinum Compounds | 1 | 2017 | 95 | 0.140 |
Why?
|
Neoplasm Proteins | 6 | 2018 | 3617 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2022 | 2010 | 0.140 |
Why?
|
Cryptorchidism | 1 | 1997 | 151 | 0.140 |
Why?
|
Benzazepines | 1 | 2018 | 310 | 0.140 |
Why?
|
SEER Program | 3 | 2019 | 1450 | 0.130 |
Why?
|
Patient Dropouts | 2 | 2012 | 412 | 0.130 |
Why?
|
DNA Methylation | 3 | 2024 | 4399 | 0.130 |
Why?
|
Microsatellite Repeats | 1 | 2018 | 784 | 0.130 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1998 | 350 | 0.130 |
Why?
|
Frameshift Mutation | 1 | 2018 | 392 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 165 | 0.130 |
Why?
|
Genomic Imprinting | 1 | 1997 | 329 | 0.130 |
Why?
|
Treatment Failure | 3 | 2015 | 2644 | 0.130 |
Why?
|
Models, Economic | 1 | 2020 | 716 | 0.130 |
Why?
|
Oncogene Proteins, Viral | 3 | 2012 | 340 | 0.130 |
Why?
|
Oral Hygiene | 1 | 2016 | 132 | 0.130 |
Why?
|
Administration, Oral | 3 | 2019 | 4021 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 1997 | 662 | 0.120 |
Why?
|
Orchiectomy | 1 | 1997 | 463 | 0.120 |
Why?
|
Photochemotherapy | 2 | 1999 | 823 | 0.120 |
Why?
|
Immunophenotyping | 2 | 2017 | 1869 | 0.120 |
Why?
|
Maximum Tolerated Dose | 3 | 2019 | 883 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4853 | 0.120 |
Why?
|
Palliative Care | 4 | 2013 | 3598 | 0.120 |
Why?
|
Genomics | 3 | 2020 | 5821 | 0.120 |
Why?
|
Radiation Tolerance | 2 | 2014 | 479 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 74 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 1998 | 560 | 0.120 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 324 | 0.120 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4243 | 0.120 |
Why?
|
Tumor Microenvironment | 6 | 2024 | 3877 | 0.120 |
Why?
|
Organometallic Compounds | 1 | 1998 | 647 | 0.120 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2024 | 8552 | 0.110 |
Why?
|
Testis | 1 | 1997 | 794 | 0.110 |
Why?
|
Morpholines | 1 | 2017 | 581 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2019 | 3639 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 2 | 2014 | 2803 | 0.110 |
Why?
|
Lactococcus lactis | 1 | 2013 | 29 | 0.110 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2018 | 328 | 0.110 |
Why?
|
Laryngoscopy | 2 | 2012 | 707 | 0.110 |
Why?
|
Mucous Membrane | 2 | 2019 | 659 | 0.110 |
Why?
|
Urinary Bladder | 2 | 2022 | 1152 | 0.110 |
Why?
|
Folic Acid | 2 | 2012 | 1323 | 0.110 |
Why?
|
Marital Status | 1 | 2014 | 426 | 0.110 |
Why?
|
Aminopyridines | 1 | 2017 | 573 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1722 | 0.110 |
Why?
|
Chromosome Mapping | 2 | 2000 | 4615 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 106 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2057 | 0.100 |
Why?
|
Radiopharmaceuticals | 5 | 2022 | 2651 | 0.100 |
Why?
|
Leukoplakia, Oral | 2 | 2024 | 77 | 0.100 |
Why?
|
Respiratory Function Tests | 1 | 1997 | 1682 | 0.100 |
Why?
|
Wounds, Nonpenetrating | 1 | 1999 | 807 | 0.100 |
Why?
|
Calcitonin | 2 | 2010 | 329 | 0.100 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 214 | 0.100 |
Why?
|
Down Syndrome | 2 | 2012 | 901 | 0.100 |
Why?
|
Genes, erbB-2 | 1 | 2012 | 162 | 0.100 |
Why?
|
Thyroid Gland | 1 | 2018 | 1169 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3162 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2021 | 2571 | 0.100 |
Why?
|
Positron-Emission Tomography | 5 | 2022 | 6485 | 0.100 |
Why?
|
Etazolate | 1 | 2011 | 1 | 0.100 |
Why?
|
Proto-Oncogenes | 1 | 2012 | 321 | 0.100 |
Why?
|
Esophagoscopy | 1 | 2013 | 396 | 0.090 |
Why?
|
Radioimmunodetection | 2 | 2001 | 45 | 0.090 |
Why?
|
Cohort Studies | 12 | 2021 | 41493 | 0.090 |
Why?
|
Gastrostomy | 2 | 2011 | 323 | 0.090 |
Why?
|
Feasibility Studies | 4 | 2019 | 5247 | 0.090 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2006 | 621 | 0.090 |
Why?
|
Carcinoembryonic Antigen | 2 | 2010 | 337 | 0.090 |
Why?
|
Patient Education as Topic | 3 | 2015 | 2319 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 9 | 2023 | 20571 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1667 | 0.090 |
Why?
|
Mouth Mucosa | 2 | 2013 | 432 | 0.090 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2011 | 214 | 0.090 |
Why?
|
Biopsy | 3 | 2018 | 6766 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5315 | 0.090 |
Why?
|
Axilla | 1 | 2012 | 624 | 0.080 |
Why?
|
Indoles | 1 | 1998 | 1833 | 0.080 |
Why?
|
Acetylation | 1 | 2012 | 1055 | 0.080 |
Why?
|
Incidence | 5 | 2019 | 21355 | 0.080 |
Why?
|
DNA-Binding Proteins | 4 | 2020 | 9610 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2022 | 1661 | 0.080 |
Why?
|
Nutrition Policy | 1 | 2013 | 471 | 0.080 |
Why?
|
Intubation, Gastrointestinal | 1 | 2010 | 166 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18398 | 0.080 |
Why?
|
Health Resources | 1 | 2015 | 935 | 0.080 |
Why?
|
Receptors, Somatomedin | 1 | 2008 | 57 | 0.080 |
Why?
|
Meta-Analysis as Topic | 2 | 2016 | 1380 | 0.080 |
Why?
|
Host-Pathogen Interactions | 2 | 2014 | 1459 | 0.080 |
Why?
|
Doxorubicin | 1 | 2015 | 2224 | 0.080 |
Why?
|
Octreotide | 2 | 2000 | 153 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7391 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2009 | 10766 | 0.080 |
Why?
|
Enteral Nutrition | 2 | 2013 | 794 | 0.080 |
Why?
|
Codon | 1 | 2010 | 601 | 0.080 |
Why?
|
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2007 | 28 | 0.080 |
Why?
|
Coronary Artery Bypass | 1 | 1997 | 2188 | 0.070 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 681 | 0.070 |
Why?
|
Antineoplastic Protocols | 2 | 2006 | 48 | 0.070 |
Why?
|
Oral Ulcer | 1 | 2008 | 96 | 0.070 |
Why?
|
Phosphotransferases | 1 | 2008 | 303 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1835 | 0.070 |
Why?
|
Coronary Disease | 1 | 2022 | 5914 | 0.070 |
Why?
|
Pelvis | 2 | 2022 | 733 | 0.070 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 50 | 0.070 |
Why?
|
Sweat | 1 | 2007 | 56 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1533 | 0.070 |
Why?
|
Survivors | 1 | 2018 | 2371 | 0.070 |
Why?
|
Cancer Care Facilities | 3 | 2019 | 422 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5492 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2510 | 0.070 |
Why?
|
Pilomatrixoma | 1 | 2006 | 24 | 0.070 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 312 | 0.070 |
Why?
|
Neoplasms, Second Primary | 3 | 2010 | 1052 | 0.070 |
Why?
|
Radiation Dosage | 2 | 2022 | 1958 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5672 | 0.070 |
Why?
|
Predictive Value of Tests | 8 | 2019 | 15266 | 0.070 |
Why?
|
Lichen Planus, Oral | 1 | 2007 | 57 | 0.070 |
Why?
|
Vitamin B 6 | 1 | 2007 | 234 | 0.070 |
Why?
|
Dyspepsia | 1 | 2007 | 116 | 0.070 |
Why?
|
Societies, Medical | 1 | 2018 | 3905 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2017 | 3713 | 0.070 |
Why?
|
Therapeutic Irrigation | 2 | 2019 | 292 | 0.070 |
Why?
|
Epithelium | 1 | 2011 | 1603 | 0.070 |
Why?
|
Ki-67 Antigen | 2 | 2008 | 629 | 0.070 |
Why?
|
Repressor Proteins | 3 | 2012 | 2986 | 0.070 |
Why?
|
Hair Diseases | 1 | 2006 | 72 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1486 | 0.070 |
Why?
|
Tubulin | 1 | 2009 | 693 | 0.070 |
Why?
|
Comorbidity | 3 | 2017 | 10508 | 0.060 |
Why?
|
Reproducibility of Results | 5 | 2023 | 20099 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2020 | 5799 | 0.060 |
Why?
|
Gastroscopy | 2 | 2004 | 211 | 0.060 |
Why?
|
Lymph Node Excision | 3 | 2001 | 1271 | 0.060 |
Why?
|
Guidelines as Topic | 3 | 2018 | 1386 | 0.060 |
Why?
|
Liver Neoplasms | 2 | 2000 | 4319 | 0.060 |
Why?
|
Submandibular Gland | 1 | 2005 | 87 | 0.060 |
Why?
|
Health Status | 2 | 2017 | 4077 | 0.060 |
Why?
|
Brachytherapy | 1 | 2013 | 1223 | 0.060 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2007 | 362 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3358 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 548 | 0.060 |
Why?
|
United States | 5 | 2020 | 72335 | 0.060 |
Why?
|
Vitamin B 12 | 1 | 2007 | 524 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2008 | 571 | 0.060 |
Why?
|
Radiotherapy | 2 | 2008 | 1499 | 0.060 |
Why?
|
Blood Cells | 1 | 2006 | 305 | 0.060 |
Why?
|
Kidney Transplantation | 3 | 2013 | 4235 | 0.060 |
Why?
|
Nausea | 1 | 2007 | 679 | 0.060 |
Why?
|
Mucositis | 2 | 2019 | 108 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 3597 | 0.060 |
Why?
|
Genomic Instability | 1 | 2008 | 709 | 0.060 |
Why?
|
Withholding Treatment | 1 | 2008 | 617 | 0.060 |
Why?
|
Pleurodesis | 1 | 2004 | 46 | 0.060 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1927 | 0.060 |
Why?
|
Barium Sulfate | 1 | 2004 | 180 | 0.060 |
Why?
|
Time Factors | 9 | 2020 | 39970 | 0.050 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2004 | 283 | 0.050 |
Why?
|
Mesna | 1 | 2003 | 62 | 0.050 |
Why?
|
Postoperative Period | 2 | 2019 | 1814 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2012 | 3492 | 0.050 |
Why?
|
Patient Preference | 1 | 2011 | 924 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12463 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9031 | 0.050 |
Why?
|
Topotecan | 1 | 2003 | 132 | 0.050 |
Why?
|
CREB-Binding Protein | 1 | 2023 | 148 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3052 | 0.050 |
Why?
|
Animals | 14 | 2023 | 168467 | 0.050 |
Why?
|
X-Rays | 1 | 2024 | 307 | 0.050 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2003 | 107 | 0.050 |
Why?
|
Transcription Factors | 2 | 2020 | 12129 | 0.050 |
Why?
|
Genetic Markers | 2 | 2000 | 2601 | 0.050 |
Why?
|
Survival | 1 | 2003 | 161 | 0.050 |
Why?
|
Ifosfamide | 1 | 2003 | 232 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2008 | 785 | 0.050 |
Why?
|
Recovery of Function | 2 | 2011 | 2979 | 0.050 |
Why?
|
Pleura | 1 | 2004 | 245 | 0.050 |
Why?
|
Receptor, Notch1 | 2 | 2016 | 496 | 0.050 |
Why?
|
Valsalva Maneuver | 1 | 2022 | 99 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2024 | 2201 | 0.050 |
Why?
|
Pancreatitis | 2 | 2000 | 1096 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2008 | 909 | 0.050 |
Why?
|
Psychophysiologic Disorders | 1 | 2004 | 221 | 0.050 |
Why?
|
Adolescent | 11 | 2018 | 88324 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2005 | 696 | 0.050 |
Why?
|
Health Personnel | 1 | 2015 | 3335 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2007 | 15633 | 0.050 |
Why?
|
Acetylene | 1 | 2001 | 8 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1578 | 0.050 |
Why?
|
Pandemics | 4 | 2022 | 8656 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4425 | 0.050 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9420 | 0.050 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2001 | 79 | 0.050 |
Why?
|
Parotid Gland | 1 | 2022 | 175 | 0.050 |
Why?
|
Proteome | 1 | 2011 | 1862 | 0.050 |
Why?
|
Hand Injuries | 1 | 1984 | 239 | 0.050 |
Why?
|
Leucovorin | 1 | 2003 | 643 | 0.050 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2001 | 84 | 0.050 |
Why?
|
Prevalence | 5 | 2019 | 15732 | 0.050 |
Why?
|
Cyclin A2 | 1 | 2000 | 21 | 0.050 |
Why?
|
Antibodies, Neoplasm | 2 | 2001 | 281 | 0.050 |
Why?
|
Pyrazoles | 2 | 2008 | 2009 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10721 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2004 | 672 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4016 | 0.040 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2000 | 166 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2003 | 590 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 12975 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2003 | 629 | 0.040 |
Why?
|
Silicon Dioxide | 1 | 2001 | 216 | 0.040 |
Why?
|
Risk Factors | 10 | 2019 | 74213 | 0.040 |
Why?
|
Manometry | 1 | 2022 | 454 | 0.040 |
Why?
|
Esophageal Neoplasms | 2 | 2001 | 1654 | 0.040 |
Why?
|
Respiratory Mechanics | 1 | 2004 | 699 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4575 | 0.040 |
Why?
|
Sexual Partners | 2 | 2015 | 796 | 0.040 |
Why?
|
Organs at Risk | 1 | 2022 | 359 | 0.040 |
Why?
|
Blotting, Southern | 1 | 2000 | 777 | 0.040 |
Why?
|
Base Sequence | 3 | 2016 | 12441 | 0.040 |
Why?
|
Technology | 1 | 2022 | 292 | 0.040 |
Why?
|
Anal Canal | 1 | 2022 | 373 | 0.040 |
Why?
|
Cryptogenic Organizing Pneumonia | 1 | 1999 | 28 | 0.040 |
Why?
|
Erythema Nodosum | 1 | 1999 | 32 | 0.040 |
Why?
|
Cytokines | 2 | 2016 | 7396 | 0.040 |
Why?
|
Genes, Neoplasm | 2 | 2014 | 370 | 0.040 |
Why?
|
Thyroglobulin | 2 | 2010 | 111 | 0.040 |
Why?
|
Smoke Inhalation Injury | 1 | 1999 | 47 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7967 | 0.040 |
Why?
|
Progesterone | 1 | 2003 | 742 | 0.040 |
Why?
|
S Phase | 1 | 2000 | 421 | 0.040 |
Why?
|
Pressure | 1 | 2022 | 1154 | 0.040 |
Why?
|
Rhenium | 1 | 1998 | 14 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1756 | 0.040 |
Why?
|
Smoking | 2 | 2016 | 9053 | 0.040 |
Why?
|
Antipsychotic Agents | 1 | 2012 | 3067 | 0.040 |
Why?
|
Sensitivity and Specificity | 5 | 2019 | 14666 | 0.040 |
Why?
|
Aminolevulinic Acid | 1 | 1999 | 144 | 0.040 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2019 | 81 | 0.040 |
Why?
|
Germany | 1 | 2021 | 875 | 0.040 |
Why?
|
Blotting, Northern | 1 | 2000 | 1545 | 0.040 |
Why?
|
Signal Transduction | 3 | 2018 | 23447 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2003 | 877 | 0.040 |
Why?
|
Peritonitis | 1 | 2001 | 368 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2872 | 0.040 |
Why?
|
Technetium | 1 | 1998 | 317 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2023 | 738 | 0.040 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2000 | 592 | 0.040 |
Why?
|
Mice | 6 | 2023 | 81533 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 153 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1040 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 397 | 0.040 |
Why?
|
Cell Transformation, Viral | 1 | 2019 | 526 | 0.040 |
Why?
|
Skin Temperature | 1 | 1998 | 96 | 0.040 |
Why?
|
Somatostatin | 1 | 2000 | 447 | 0.040 |
Why?
|
Pelvic Neoplasms | 1 | 2000 | 247 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 2013 | 1900 | 0.040 |
Why?
|
Radiography | 3 | 2014 | 6965 | 0.040 |
Why?
|
Body Fluids | 1 | 2019 | 320 | 0.040 |
Why?
|
Constipation | 1 | 2022 | 563 | 0.040 |
Why?
|
Rectum | 1 | 2022 | 892 | 0.040 |
Why?
|
Urinary Bladder, Neurogenic | 1 | 2019 | 173 | 0.040 |
Why?
|
Risk Assessment | 4 | 2019 | 23996 | 0.040 |
Why?
|
Random Allocation | 2 | 2001 | 2395 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11122 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3449 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2023 | 16986 | 0.040 |
Why?
|
Bandages | 1 | 1999 | 269 | 0.030 |
Why?
|
Neck | 2 | 2016 | 734 | 0.030 |
Why?
|
Hyperhomocysteinemia | 2 | 2007 | 118 | 0.030 |
Why?
|
Mandible | 1 | 2021 | 753 | 0.030 |
Why?
|
Jaw | 1 | 2017 | 93 | 0.030 |
Why?
|
Catheterization | 1 | 2022 | 1428 | 0.030 |
Why?
|
Anorexia | 1 | 2017 | 154 | 0.030 |
Why?
|
Vagina | 1 | 2022 | 838 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1667 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17904 | 0.030 |
Why?
|
Estrogens | 1 | 2003 | 1522 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2008 | 882 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2000 | 9541 | 0.030 |
Why?
|
Crosses, Genetic | 1 | 1997 | 749 | 0.030 |
Why?
|
Sensation Disorders | 1 | 2017 | 160 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2004 | 1182 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2015 | 4544 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Brazil | 2 | 2012 | 1230 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3810 | 0.030 |
Why?
|
Cell Cycle | 1 | 2004 | 2932 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2000 | 767 | 0.030 |
Why?
|
Neutron Capture Therapy | 1 | 2015 | 6 | 0.030 |
Why?
|
Abdominal Muscles | 1 | 1996 | 169 | 0.030 |
Why?
|
Injections | 1 | 2019 | 831 | 0.030 |
Why?
|
International Agencies | 1 | 2016 | 243 | 0.030 |
Why?
|
CpG Islands | 1 | 2000 | 1230 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 26127 | 0.030 |
Why?
|
Nanotechnology | 1 | 2001 | 714 | 0.030 |
Why?
|
Tobacco Use Disorder | 2 | 2011 | 703 | 0.030 |
Why?
|
Social Participation | 1 | 2017 | 183 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2000 | 732 | 0.030 |
Why?
|
Photosensitizing Agents | 1 | 1999 | 623 | 0.030 |
Why?
|
Infant | 6 | 2016 | 36192 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 612 | 0.030 |
Why?
|
Hormones | 1 | 1999 | 869 | 0.030 |
Why?
|
Eating | 2 | 2013 | 1539 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2917 | 0.030 |
Why?
|
DNA Helicases | 1 | 2020 | 851 | 0.030 |
Why?
|
Administration, Intravesical | 1 | 2014 | 92 | 0.030 |
Why?
|
Receptor, Notch2 | 1 | 2015 | 87 | 0.030 |
Why?
|
Radiation Oncology | 1 | 2021 | 563 | 0.030 |
Why?
|
Child, Preschool | 6 | 2016 | 42230 | 0.030 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2015 | 94 | 0.030 |
Why?
|
Single-Blind Method | 1 | 1998 | 1574 | 0.030 |
Why?
|
Genotype | 3 | 2012 | 12990 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 846 | 0.030 |
Why?
|
Gene Dosage | 1 | 2018 | 1218 | 0.030 |
Why?
|
Analysis of Variance | 3 | 2011 | 6228 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 451 | 0.030 |
Why?
|
Polymers | 1 | 2001 | 1617 | 0.030 |
Why?
|
Schizophrenia | 1 | 2012 | 6937 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2004 | 6019 | 0.030 |
Why?
|
Rats, Wistar | 3 | 2004 | 1848 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3606 | 0.030 |
Why?
|
Phosphorylation | 1 | 2004 | 8321 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 2691 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13255 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1998 | 1334 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21017 | 0.030 |
Why?
|
Methylmalonic Acid | 1 | 2012 | 49 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2015 | 4740 | 0.030 |
Why?
|
Apoptosis | 1 | 2008 | 9489 | 0.030 |
Why?
|
Niacinamide | 1 | 2014 | 413 | 0.030 |
Why?
|
Virus Integration | 1 | 2014 | 304 | 0.030 |
Why?
|
Psychometrics | 1 | 2022 | 3065 | 0.030 |
Why?
|
Immunity | 1 | 2018 | 996 | 0.030 |
Why?
|
Burns | 1 | 1984 | 1882 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15501 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2012 | 228 | 0.020 |
Why?
|
Interleukin-3 | 1 | 2013 | 425 | 0.020 |
Why?
|
Pancreas Transplantation | 1 | 2013 | 197 | 0.020 |
Why?
|
Quality Improvement | 2 | 2019 | 3801 | 0.020 |
Why?
|
History, 21st Century | 1 | 2018 | 1567 | 0.020 |
Why?
|
Lebanon | 1 | 2012 | 245 | 0.020 |
Why?
|
Carbon | 1 | 2015 | 666 | 0.020 |
Why?
|
Antibody Formation | 1 | 2016 | 1395 | 0.020 |
Why?
|
Dimerization | 1 | 2013 | 891 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 670 | 0.020 |
Why?
|
Administration, Topical | 1 | 2013 | 704 | 0.020 |
Why?
|
Indazoles | 1 | 2013 | 304 | 0.020 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2012 | 118 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2016 | 22176 | 0.020 |
Why?
|
Recurrence | 2 | 2020 | 8466 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1410 | 0.020 |
Why?
|
Up-Regulation | 1 | 2000 | 4124 | 0.020 |
Why?
|
Cell Movement | 1 | 2023 | 5205 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2007 | 15936 | 0.020 |
Why?
|
Disease Models, Animal | 3 | 2001 | 18253 | 0.020 |
Why?
|
Cotinine | 1 | 2011 | 206 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3123 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2001 | 6935 | 0.020 |
Why?
|
Syndrome | 1 | 2017 | 3267 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2013 | 2827 | 0.020 |
Why?
|
Cicatrix | 1 | 1996 | 798 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1626 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 1935 | 0.020 |
Why?
|
Transplantation, Homologous | 2 | 2011 | 4807 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1560 | 0.020 |
Why?
|
Severity of Illness Index | 4 | 2011 | 15843 | 0.020 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 89 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2020 | 0.020 |
Why?
|
Models, Genetic | 1 | 2000 | 3442 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4346 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3677 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2010 | 427 | 0.020 |
Why?
|
False Positive Reactions | 2 | 2004 | 957 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2011 | 8601 | 0.020 |
Why?
|
Esophagitis | 1 | 2010 | 164 | 0.020 |
Why?
|
Dyspnea | 1 | 2017 | 1347 | 0.020 |
Why?
|
Albumins | 1 | 2012 | 575 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3332 | 0.020 |
Why?
|
Child | 6 | 2016 | 80156 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7213 | 0.020 |
Why?
|
Dermatitis | 1 | 2010 | 202 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 897 | 0.020 |
Why?
|
Endometriosis | 1 | 1996 | 870 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2011 | 547 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 11670 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 2242 | 0.020 |
Why?
|
Diet | 1 | 2006 | 8075 | 0.020 |
Why?
|
Cell Survival | 1 | 1998 | 5791 | 0.020 |
Why?
|
Boston | 2 | 2011 | 9326 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2007 | 3416 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2013 | 857 | 0.020 |
Why?
|
HIV Infections | 1 | 2014 | 17352 | 0.020 |
Why?
|
Fibrosis | 2 | 2005 | 2049 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1705 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2014 | 1048 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2007 | 372 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3614 | 0.020 |
Why?
|
Protein Conformation | 1 | 2014 | 3968 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2016 | 26198 | 0.020 |
Why?
|
Adenoma, Oxyphilic | 1 | 2008 | 148 | 0.020 |
Why?
|
Alleles | 1 | 1997 | 6864 | 0.020 |
Why?
|
Ligands | 1 | 2013 | 3272 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1998 | 2538 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 597 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2013 | 1315 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 1997 | 2630 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 2009 | 728 | 0.020 |
Why?
|
Dinoprostone | 1 | 2008 | 597 | 0.020 |
Why?
|
Laparoscopy | 1 | 1997 | 2036 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2007 | 679 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2001 | 4527 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2001 | 2218 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 1745 | 0.020 |
Why?
|
Histology | 1 | 2004 | 16 | 0.010 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2008 | 323 | 0.010 |
Why?
|
Functional Residual Capacity | 1 | 2004 | 70 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11530 | 0.010 |
Why?
|
Pharynx | 1 | 2007 | 432 | 0.010 |
Why?
|
Occlusive Dressings | 1 | 1984 | 52 | 0.010 |
Why?
|
Lung Compliance | 1 | 2004 | 200 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1468 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 134 | 0.010 |
Why?
|
Length of Stay | 1 | 1997 | 6426 | 0.010 |
Why?
|
Organ Specificity | 1 | 2008 | 1968 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4028 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2735 | 0.010 |
Why?
|
Physical Examination | 1 | 2009 | 1255 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 2003 | 384 | 0.010 |
Why?
|
Counseling | 1 | 2011 | 1547 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36429 | 0.010 |
Why?
|
Salivary Glands | 1 | 2004 | 229 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5872 | 0.010 |
Why?
|
Pain | 1 | 2017 | 5073 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1406 | 0.010 |
Why?
|
Liver | 1 | 1997 | 7529 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17635 | 0.010 |
Why?
|
Data Collection | 1 | 2011 | 3322 | 0.010 |
Why?
|
Creatinine | 1 | 2007 | 1899 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1096 | 0.010 |
Why?
|
Cell Death | 1 | 2006 | 1679 | 0.010 |
Why?
|
Pyrimidines | 1 | 2013 | 3028 | 0.010 |
Why?
|
Rats | 3 | 2004 | 23741 | 0.010 |
Why?
|
Heterozygote | 1 | 2007 | 2787 | 0.010 |
Why?
|
Thorax | 1 | 2004 | 555 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2001 | 510 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2001 | 150 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2007 | 2192 | 0.010 |
Why?
|
Respiratory System | 1 | 2004 | 563 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2015 | 4330 | 0.010 |
Why?
|
Medical History Taking | 1 | 2004 | 774 | 0.010 |
Why?
|
Menstrual Cycle | 1 | 2003 | 539 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2521 | 0.010 |
Why?
|
Phenotype | 1 | 1997 | 16592 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22172 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2004 | 1008 | 0.010 |
Why?
|
Patient Compliance | 1 | 2009 | 2690 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1896 | 0.010 |
Why?
|
Gene Deletion | 1 | 2007 | 2665 | 0.010 |
Why?
|
Burkitt Lymphoma | 1 | 2001 | 335 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2000 | 573 | 0.010 |
Why?
|
Acute Disease | 2 | 2000 | 7237 | 0.010 |
Why?
|
Health Promotion | 1 | 2011 | 2214 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1984 | 1083 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2011 | 3029 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2013 | 3415 | 0.010 |
Why?
|
Medical Records | 1 | 2004 | 1408 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 1984 | 1668 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3778 | 0.010 |
Why?
|
Clone Cells | 1 | 2001 | 1659 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2001 | 2561 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2009 | 1852 | 0.010 |
Why?
|
Observer Variation | 1 | 2004 | 2606 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4811 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2001 | 983 | 0.010 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 1988 | 0.010 |
Why?
|
Esophagectomy | 1 | 2001 | 468 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2001 | 1702 | 0.010 |
Why?
|
Postpartum Period | 1 | 2003 | 1173 | 0.010 |
Why?
|
Probability | 1 | 2001 | 2477 | 0.010 |
Why?
|
Surgical Flaps | 1 | 1984 | 1671 | 0.010 |
Why?
|
Biosensing Techniques | 1 | 2001 | 650 | 0.010 |
Why?
|
Inflammation | 2 | 2005 | 10773 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2001 | 940 | 0.010 |
Why?
|
Environmental Monitoring | 1 | 2001 | 1460 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1998 | 1972 | 0.010 |
Why?
|
Reference Values | 1 | 2001 | 4920 | 0.010 |
Why?
|
Chronic Disease | 1 | 2007 | 9319 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2004 | 3249 | 0.010 |
Why?
|
Sex Factors | 1 | 1984 | 10553 | 0.010 |
Why?
|
Pregnancy | 2 | 2003 | 29876 | 0.000 |
Why?
|
Cesarean Section | 1 | 1996 | 1398 | 0.000 |
Why?
|
Lung | 1 | 1999 | 10002 | 0.000 |
Why?
|